GILEAD SCIENCES INC (GIS.DE) Stock Price, Quote, News and Overview
FRA:GIS - Deutsche Boerse Ag - US3755581036 - Common Stock - Currency: EUR
GIS.DE Quote, Performance and Key Statistics
GILEAD SCIENCES INC
FRA:GIS (2/4/2025, 7:00:00 PM)
94.23
-2.17 (-2.25%)
The current stock price of GIS.DE is 94.23 EUR. In the past month the price increased by 7.68%. In the past year, price increased by 38.17%.
GIS.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.69 | 323.32B | ||
| AMG.DE | AMGEN INC | 14.96 | 149.57B | ||
| 1AMGN.MI | AMGEN INC | 14.81 | 148.09B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 937.76 | 118.34B | ||
| ARGX.BR | ARGENX SE | N/A | 37.52B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 27.07B | ||
| IDP.DE | BIOGEN INC | 8.75 | 20.15B | ||
| 1MRNA.MI | MODERNA INC | N/A | 13.08B | ||
| 0QF.DE | MODERNA INC | N/A | 12.75B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.95B | ||
| GLPG.AS | GALAPAGOS NV | 6.98 | 1.44B | ||
| NVV1.DE | NOVAVAX INC | N/A | 1.30B |
Related stock screener links
About GIS.DE
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 18,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. The company is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The firm operates in more than 35 countries.
Company Info
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA US
Employees: 18000
Company Website: https://www.gilead.com/
Investor Relations: https://investors.gilead.com/
Phone: 16505743000
GIS.DE FAQ
What is the stock price of GIS.DE?
The current stock price of GIS.DE is 94.23 EUR.
What is the symbol for GILEAD SCIENCES INC stock?
The exchange symbol of GILEAD SCIENCES INC is GIS and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is GIS.DE stock listed?
GIS.DE stock is listed on the Deutsche Boerse Ag exchange.
Is GIS.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for GIS.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of GIS.DE.
Does GIS.DE stock pay dividends?
GIS.DE has a dividend yield of 3.18%. The yearly dividend amount is currently 3.06.
When does GIS.DE stock report earnings?
GIS.DE will report earnings on 2025-02-11, after the market close.
What is the Price/Earnings (PE) ratio of GIS.DE?
The PE ratio for GIS.DE is 21.97. This is based on the reported non-GAAP earnings per share of 4.29 and the current share price of 94.23 EUR.
GIS.DE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GIS.DE. When comparing the yearly performance of all stocks, GIS.DE is one of the better performing stocks in the market, outperforming 90.26% of all stocks.
GIS.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GIS.DE. GIS.DE has an excellent profitability rating, but there are some minor concerns on its financial health.
GIS.DE Financial Highlights
Over the last trailing twelve months GIS.DE reported a non-GAAP Earnings per Share(EPS) of 4.29. The EPS increased by -36.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.45% | ||
| ROA | 0.23% | ||
| ROE | 0.69% | ||
| Debt/Equity | 0 |
GIS.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to GIS.DE. The Buy consensus is the average rating of analysts ratings from 38 analysts.
For the next year, analysts expect an EPS growth of -36.08% and a revenue growth 4.47% for GIS.DE